BridgeBio Oncology Therapeutics, Inc.
BBOTFigures shown here come from public SEC filings. Dates beside each section show the available history.
How BridgeBio Oncology Therapeutics, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 3 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2024-02-13 | Chen Bihua · CEO and Chairperson | Class A Ordinary Shares | P — Open market or private purchase | +1,427,040 | 10.00 | SEC filing |
| 2024-02-13 | Chen Bihua · CEO and Chairperson | Class A Ordinary Shares | P — Open market or private purchase | +69,360 | 10.00 | SEC filing |
| 2024-02-13 | Chen Bihua · CEO and Chairperson | Class A Ordinary Shares | P — Open market or private purchase | +903,600 | 10.00 | SEC filing |
Showing 3 of 3 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-16 | Lebowitz Peter F · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +7,289 | SEC filing |
| 2026-06-16 | Kumar Neil · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,675 | SEC filing |
| 2026-06-16 | Chen Bihua · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,675 | SEC filing |
| 2026-06-16 | MCCORMICK FRANK · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,675 | SEC filing |
| 2026-06-16 | Bauer Jake · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,675 | SEC filing |
| 2026-06-16 | Kelleher Raymond J. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,675 | SEC filing |
| 2026-06-16 | Tipirneni Praveen P. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,675 | SEC filing |
| 2026-05-10 | Beltran Pedro · President and CEO | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +1,103,837 | SEC filing |
Showing 8 of 21 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-12-10 | Wallace Eli M. · Chief Executive Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −1,114,400 | SEC filing |
| 2025-10-10 | BridgeBio Pharma, Inc. · 10% owner | Common Stock | J — Other acquisition or disposition | +784,720 | SEC filing |
| 2025-08-11 | Chen Bihua · Director, 10% owner | Common Stock | D — Disposition to the issuer | −152,940 | SEC filing |
| 2025-08-11 | Chen Bihua · Director, 10% owner | Class B ordinary shares | D — Disposition to the issuer | −307,874 | SEC filing |
| 2025-02-08 | Chen Bihua · CEO and Chairperson | Class B Ordinary Shares | J — Other acquisition or disposition | −30,000 | SEC filing |
| 2025-02-08 | Helix Holdings II LLC · Director, 10% owner | Class B Ordinary Shares | J — Other acquisition or disposition | −30,000 | SEC filing |
Showing 6 of 6 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.